Harmony Grove blends evidence-based, and holistic outpatient treatment and community partnerships for MAT to create an ...

Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, ...

Keaton Herzer tells PEOPLE a newer targeted therapy unexpectedly shrank his tumors enough to qualify for a liver transplant ...

Aura Biosciences (NASDAQ:AURA) is shifting its focus toward regulatory preparation and commercialization planning as enrollment in its registrational CoMpass study of bel-sar in early choroidal ...

Oncologists weigh second-line options after ICI failure in metastatic ccRCC, spotlighting lenvatinib/everolimus, new agents, ...

The American Cancer Society (ACS) updated its guidelines Wednesday to include two new screening options for colorectal cancer ...

For decades, families have been told there was no cure for Duchenne Muscular Dystrophy, or DMD, a rare genetic condition that causes muscles to weaken over time, and few treatment options. But today, ...

Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority Review by the FDA reiterates the serious unmet need for trea ...

For decades, patients rarely questioned their doctors. A diagnosis was usually accepted without hesitation. But, today, ...

Experimental osteoarthritis therapies repaired damaged joints in animals and may enter clinical trials within 18 months. A ...

LifeArc partners with Elpida Therapeutics to advance three gene therapies for ultra-rare neurodegenerative diseases in childrenLifeArc provides tailored clinical, translational and regulatory ...

The U.S. Food and Drug Administration on Wednesday approved AbbVie's drug to treat blastic plasmacytoid dendritic cell ...